Abstract
This study investigated the clinical features and expression levels of hypothalamic-pituitary-gonadal (HPG) axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). Retrospective analysis of 26 LGSC patients and 52 HGSC patients revealed that LGSC has a distinct hormonal profile, with significantly higher receptor expression levels (e.g., 100% GnRHR expression). LGSC patients showed a higher 5-year overall survival rate (67.5%) compared to HGSC (47.9%). Positive hormone receptor expression tended to correlate with better prognosis, suggesting these receptors as potential therapeutic targets for chemo-resistant LGSC.
Introduction
Ovarian cancer is not a single disease but a collection of distinct subtypes. Low-grade serous ovarian cancer (LGSC) accounts for less than 10% of cases and is characterized by slow growth and resistance to standard platinum-based chemotherapy. Unlike the more common high-grade serous ovarian cancer (HGSC), LGSC is thought to be hormonally driven. While estrogen (ER) and progesterone (PR) receptors are commonly evaluated, the role of the broader hypothalamic-pituitary-gonadal (HPG) axis receptors remains less understood. This study characterizes these receptors to identify new prognostic markers and therapeutic avenues.
Methods
The study retrospectively analyzed 26 patients with LGSC and 52 randomly selected HGSC patients from the Fudan University Shanghai Cancer Center (2005–2013). Tissue microarrays (TMAs) were used to perform immunohistochemistry (IHC) for six receptors: ER, PR, AR, FSHR, LHR, and GnRHR. Survival analysis was performed using Kaplan-Meier curves.
Results
Hormonal Expression Profile
LGSC tumors demonstrated a significantly higher prevalence of HPG-axis receptors compared to HGSC. Notably, GnRHR was expressed in 100% of LGSC cases. Other receptors also showed high expression: FSHR (84.0%), ER (80.8%), LHR (65.4%), AR (53.8%), and PR (34.6%). In contrast, HGSC showed much lower rates, particularly for PR (9.8%). These findings underscore the biological distinction between the two grades.
Survival and Prognosis
LGSC patients had a significantly better overall survival (OS) than HGSC patients, with a 5-year OS rate of 67.5% versus 47.9%.
While patients with positive hormone receptor expression tended to have better outcomes, the difference was not statistically significant, likely due to the small cohort size.
Discussion
The high expression of HPG-axis receptors, particularly GnRHR and FSHR, suggests that LGSC is a hormonally active tumor. Given that only 57.7% of LGSC patients in this study were sensitive to platinum-based chemotherapy, these receptors represent promising targets for alternative therapies. Targeted hormonal agents could potentially improve outcomes for patients with this chemo-resistant subtype.
Conclusion
LGSC is a distinct clinical entity with a unique hormonal landscape. The universal expression of GnRHR and high prevalence of FSHR provide a strong rationale for exploring targeted hormonal therapies in future clinical trials. Larger, multicenter studies are needed to confirm these findings and establish these receptors as definitive prognostic markers.
Summary updated